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Differential roles of the ubiquitin proteasome system and
autophagy in the clearance of soluble and aggregated
TDP-43 species
Emma L. Scotter1, Caroline Vance1, Agnes L. Nishimura1, Youn-Bok Lee1, Han-Jou Chen1, Hazel Urwin1,
Valentina Sardone1,2, Jacqueline C. Mitchell1, Boris Rogelj1,3, David C. Rubinsztein4 and Christopher E. Shaw1,*
ABSTRACT
TAR DNA-binding protein (TDP-43, also known as TARDBP) is the
major pathological protein in amyotrophic lateral sclerosis (ALS)
and frontotemporal dementia (FTD). Large TDP-43 aggregates that
are decorated with degradation adaptor proteins are seen in the
cytoplasm of remaining neurons in ALS and FTD patients post
mortem. TDP-43 accumulation and ALS-linked mutations within
degradation pathways implicate failed TDP-43 clearance as a
primary disease mechanism. Here, we report the differing roles of
the ubiquitin proteasome system (UPS) and autophagy in the
clearance of TDP-43. We have investigated the effects of inhibitors
of the UPS and autophagy on the degradation, localisation and
mobility of soluble and insoluble TDP-43. We find that soluble TDP-
43 is degraded primarily by the UPS, whereas the clearance of
aggregated TDP-43 requires autophagy. Cellular macroaggregates,
which recapitulate many of the pathological features of the
aggregates in patients, are reversible when both the UPS and
autophagy are functional. Their clearance involves the autophagic
removal of oligomeric TDP-43. We speculate that, in addition to an
age-related decline in pathway activity, a second hit in either the
UPS or the autophagy pathway drives the accumulation of TDP-43
in ALS and FTD. Therapies for clearing excess TDP-43 should
therefore target a combination of these pathways.
KEY WORDS: TDP-43, ALS, Autophagy, Proteasome, Aggrephagy,
UPS
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia
(FTD) are neurodegenerative diseases that are characterised by
the deposition of pathological protein aggregates composed of
TAR DNA-binding protein 43 (TDP-43 or TARDBP) (Neumann
et al., 2006). These ‘TDP-43 proteinopathies’ span a clinical
spectrum, from predominantly upper- and lower-motor-neuron
pathology in ALS to predominantly cortical-neuron pathology
in FTD to a mixed presentation of both. TDP-43 is a DNA-
and RNA-binding protein that regulates mRNA processing
and trafficking, the stress granule response and microRNA
biogenesis (Buratti et al., 2010; Colombrita et al., 2009; Gregory
et al., 2004; Tollervey et al., 2011). A causative role for TDP-43
in disease was confirmed by the finding that mutations in TDP-43
cause ALS, accounting for ,3% of familial and 0.5% of sporadic
cases (Lagier-Tourenne and Cleveland, 2009). In the absence of
genomic mutation, wild-type TDP-43 aggregates are found in the
brain and spinal cord of 90% of ALS patients and in the brain of
60% of FTD patients (Neumann et al., 2006).
Evidence that the dysregulation of TDP-43 can cause disease
comes from many animal models. A neurodegenerative ALS-
like phenotype can be generated by either overexpression or
knockdown of TDP-43 in flies, fish and mice (Kabashi et al.,
2010; Li et al., 2010; Schmid et al., 2013; Wils et al., 2010; Wu
et al., 2012). Indeed, various strands of evidence implicate a
failure of TDP-43 clearance in human ALS and FTD. The
aggregated TDP-43 that is present in ALS and FTD tissue is
phosphorylated, ubiquitylated and labelled by ubiquilin-1 and
-2 (Deng et al., 2011; Neumann et al., 2006) and sequestosome-1
(SQSTM1 or p62) (Arai et al., 2003), all of which target proteins
for degradation. In addition, mutations in ubiquilin-2 (Deng et al.,
2011), sequestosome-1 (Fecto et al., 2011) or another degradation
pathway adaptor protein, valosin-containing protein (VCP)
(Watts et al., 2004), can cause ALS and FTD characterised by
TDP-43 aggregation. Cellular studies indicate that primary
mutation of TDP-43 also confers resistance to its degradation
(Ling et al., 2010).
Two of the major pathways for cellular protein degradation are
the ubiquitin proteasome system (UPS) and macroautophagy,
herein referred to as ‘autophagy’. Autophagy has been shown
to degrade soluble and aggregated protein substrates that are
too large to enter the UPS pore (Verhoef et al., 2002).
Ubiquitylation can direct proteins towards either a UPS or an
autophagic fate, therefore ubiquitin pathology in human ALS and
FTD tissue does not distinguish which pathway is implicated in
disease pathogenesis. The adaptor proteins sequestosome-1 and
ubiquilin-2, which decorate TDP-43 aggregates, are also
associated with both the UPS and autophagy (Lamark and
Johansen, 2010).
Determining the relative importance of these two protein
degradation pathways in maintaining TDP-43 proteostasis is
challenging owing to the complex interplay between them, yet is
crucial to understanding the mechanisms underpinning TDP-43
accumulation in disease. Although the role of TDP-43
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macroaggregation remains controversial, the cytoplasmic
accumulation of TDP-43 is definitely linked to toxicity, and
therapeutic strategies designed to enhance TDP-43 clearance are
of great appeal. We therefore sought to investigate how TDP-43
protein degradation is regulated and the potential for targeting
degradative pathways as a treatment for ALS and FTD.
RESULTS
Establishing cellular models of TDP-43 proteinopathy
Stable cellular models of ALS and FTD based on doxycycline
(DOX)-inducible expression of various TDP-43 constructs
(Fig. 1A) were generated in human neuroblastoma (SH-SY5Y)
cells and human embryonic kidney (HEK293) cells. In both cell
types, and in agreement with previous reports, after induction with
1 mg/ml DOX, HA-tagged wild-type (WT) TDP-43 was
predominantly partial nuclear, TDP-43 with a deleted nuclear
localisation sequence (DNLS) was both nuclear and cytoplasmic,
and a C-terminal fragment of TDP-43 (amino acids 181–414; CTF)
was predominantly cytoplasmic (Fig. 1B,C). The partial nuclear
localisation of DNLS TDP-43 is likely to be due to its dimerisation
with endogenous TDP-43, leading to co-import. Stable SH-SY5Y
and HEK293 lines expressing enhanced GFP (EGFP)-tagged TDP-
43 WT, DNLS and CTF recapitulated these localisation profiles.
The expression of TDP-43 in both SH-SY5Y and HEK293 lines
was dependent on the dose of DOX (Fig. 1D,E, EC50; HEK293,
0.97 ng/ml; SH-SY5Y, 0.35 ng/ml).
Degradation of TDP-43
Next, we sought to investigate the relative degradation rates of the
TDP-43 constructs. Because of its ability to autoregulate (Ayala
et al., 2011), quantification of endogenous TDP-43 protein
degradation cannot be performed by steady-state analyses. We
exploited the inducible nature of our cellular model to perform non-
radioactive pulse–chase experiments, in order to assay the relative
degradation of HA–TDP-43 protein after removal of the DOX
inducer. In all experiments, HA–TDP-43 expression was induced for
24 h using 10 ng/ml DOX to achieve almost maximal expression.
In HEK293 lines assayed over 72 h (Fig. 2A), wild-type TDP-43
was degraded with a half-life of 32.5 h. The 25-kDa CTF of TDP-43,
which is predominantly cytoplasmic, was turned over far more
Fig. 1. Establishing cellular models of TDP-43
proteinopathy. (A) A schematic of TDP-43 constructs
used in this study. NES, nuclear export signal; RRM,
RNA recognition motif. (B,C) Immunocytochemical
analysis of TDP-43 expression and localisation in stable
SH-SY5Y (B) and HEK293 (C) cell lines induced to
express HA–TDP-43 constructs by a 48-h induction with
DOX, showing nuclear localisation (WT), cytoplasmic
localisation (CTF) or both (DNLS). Scale bar: 10 mm.
(D,E) Cell-based ELISA validation of DOX-dose-
dependent expression of HA–TDP WT in stable SH-
SY5Y (D) and HEK293 (E) lines after a 48-h induction
with DOX (EC50; HEK293, 0.97 ng/ml; SH-SY5Y,
0.35 ng/ml).












rapidly, with a half-life of 11 h. TDP-43 DNLS, which is both
nuclear and cytoplasmic, showed an intermediate rate of degradation,
with a half-life of 24.4 h. Previous estimates of the half-life of
untagged wild-type TDP-43 have ranged from 4 h to §34 h (Ling
et al., 2010; Pesiridis et al., 2011; Watanabe et al., 2013).
In order to verify that the assay was not simply measuring
the dilution of HA–TDP-43 protein by cell division or the
slow decay of DOX-induced transcripts, we performed a
modified experiment over a shorter timecourse in SH-SY5Y
lines (Fig. 2B), and used quantitative PCR to assess transcript
levels after DOX washout (Fig. 2C). SH-SY5Y cells have a
doubling time of ,48 h, compared to ,24 h for HEK293. In
addition, protein levels were assayed over a 24-h period that
began 24 h after DOX washout (see schematic Fig. 2B), to ensure
that DOX-induced transcripts were not still present as a substrate
for continued protein synthesis. Indeed, using real-time reverse
transcriptase PCR, we verified that HA–TDP-43 transcripts
rapidly decayed after DOX washout (Fig. 2C). Published half-
lives for the endogenous TDP-43 transcript in various cell types
range from 1.9 h to 10.3 h (Ayala et al., 2011; Schwanhäusser
et al., 2011; Sharova et al., 2009). The three HA–TDP-43 proteins
were turned over at very similar rates in SH-SY5Y cells
compared to HEK293 cells, despite the differing cell division
rates of these cell lines and the use of a shorter timecourse in
experiments using SH-SY5Y cells (t1/2; HA–TDP-43 WT, 29.2 h;
HA–TDP-43 DNLS, 16.6 h; HA–TDP-43 CTF, 10.2 h).
Involvement of the UPS and autophagy in the degradation of TDP-43
Having determined that TDP-43 degradation rates were consistent
between cell lines and timecourses, we next analysed the
pathway(s) by which TDP-43 was being degraded, using
HEK293 lines. Inhibitors of the UPS or autophagy were
included during the final 48 h of the DOX-washout period
when protein degradation occurs (for schematic see Fig. 3A).
Inhibitors were used in favour of genetic approaches in order to
achieve temporal control and homogeneity across the cell
population.
These assays examined the total complement of TDP-43, of
which ,90% was detergent-soluble (Fig. 4D,E). The degradation
of all three TDP-43 species was inhibited to varying degrees by
the panel of inhibitors tested (Fig. 3A). The autophagy inhibitor
3-methyladenine (3MA) significantly inhibited the degradation of
CTF TDP-43 (P#0.05) and, to a lesser extent, the degradation of
wild-type and DNLS TDP-43. 3MA showed minimal effect on the
autophagy reporters p62 and LC3 (microtubule-associated protein
1 light chain 3 b) at the timepoint chosen for assay of TDP-43
levels (48 h 3MA); however, shorter timecourses of 3MA
treatment revealed autophagy inhibition had occurred (Fig. 3B).
The autophagosome–lysosome fusion inhibitor bafilomycin (Baf)
only minimally inhibited the degradation of each TDP-43 species,
despite effectively inhibiting autophagy as shown by the
accumulation of LC3-II, the modified form of LC3 that
associates with autophagosome membranes (Kabeya et al.,
2000). In contrast to the moderate effects of autophagy
inhibitors, the UPS inhibitor MG132 significantly inhibited the
degradation of all three TDP-43 constructs (Fig. 3A, WT, P#0.05;
DNLS, P#0.05; CTF, P#0.001). The related UPS inhibitor
epoxomicin also caused significant accumulation of wild-type,
DNLS and CTF TDP-43 (all P#0.05). The inhibition of both
degradation pathways (by combined treatment with 3MA and
Fig. 2. Degradation of TDP-43.
(A) Degradation of HA–TDP-43 proteins in
stable HEK293 cells as assessed by DOX
pulse–chase experiments. TDP-43 CTF
was degraded far more rapidly than TDP-43
DNLS or TDP-43 WT (t1/2; HA–TDP-43 WT,
32.5 h; HA–TDP-43 DNLS, 24.4 h; HA–
TDP-43 CTF, 11 h). (B) Degradation of HA–
TDP-43 proteins in stable SH-SY5Y cells
over a shorter timecourse, and allowing a
delay after washout for the clearance of
mRNA transcripts. HA–TDP-43 protein-
degradation rates closely reflected those
seen in HEK293 cells (t1/2; HA–TDP-43 WT,
29.2 h; HA–TDP-43 DNLS, 16.6 h; HA–
TDP-43 CTF, 10.2 h). (C) The degradation
of HA–TDP-43 mRNA transcripts in stable
SH-SY5Y cells as assessed by quantitative
reverse transcriptase PCR. Transcripts for
all three constructs decayed rapidly after
DOX washout and had reached minima by
8 h (a representative experiment is shown,
n52). (A–C) Arrowheads on schematics
show the timepoints at which samples
were taken.












MG132) did not inhibit the degradation of any of the protein
constructs any more than MG132 alone. Activators of the
autophagy pathway validated these findings because the addition
of trehalose and LiCl during DOX washout substantially
accelerated the degradation of CTF TDP-43 (Fig. 3C).
UPS, but not autophagy, inhibition induces cytoplasmic TDP-43
macroaggregates
We sought to assess the phenotypic consequences of TDP-43
accumulation under either autophagic or UPS inhibition. Parallel
biochemical and immunocytochemical studies were carried out in
SH-SY5Y cells, as their large cytoplasm was more amenable to
imaging than HEK293 cells.
To investigate the localisation and accumulation of TDP-43, its
expression was induced with 1 mg/ml DOX in stable SH-SY5Y
cells in the presence of inhibitors of the UPS or autophagy
for 48 h. For both wild type and DNLS, inhibition of the UPS, but
not autophagy, caused TDP-43 accumulation, resulting in the
formation of macroaggregates (Fig. 4A). The UPS inhibitor
MG132 induced the formation of large cytoplasmic aggregates in
,20% of cells [WT, 17.4%61.3 (224 cells counted); DNLS,
25.6%63.4 (368 cells counted) (6s.e.m.)]. Epoxomicin also
induced TDP-43 macroaggregates. By contrast, neither of the
autophagy inhibitors 3MA or bafilomycin induced the formation
of ubiquitylated TDP-43 macroaggregates. Interestingly, the co-
application of MG132 and 3MA generated aggregates more
robustly in cells expressing either HA–TDP-43 WT or HA–TDP-
43 DNLS than did MG132 alone.
As shown in Fig. 1B,C, the HA–TDP-43 CTF was expressed
at extremely low levels in both SH-SY5Y and HEK293 cells and
was barely detectable by immunocytochemistry, likely because
of its rapid degradation (as shown in Fig. 2A,B). Therefore, the
localisation of the HA–TDP-43 CTF was not investigated
further. We have found that an equivalent EGFP-tagged TDP-
43 CTF forms aggregates under UPS inhibition but not under
autophagy inhibition, similar to wild-type or DNLS TDP-43.
However, the physiological relevance of the EGFP-tagged
fragment is unclear, given that we and others (Li et al., 2011)
find its steady state level to far exceed that of CTFs with small
tags.
Fig. 3. Involvement of the UPS and
autophagy in the degradation of
TDP-43. (A) The relative HA–TDP-43
remaining in stable HEK293 cells at
72 h post-DOX washout, with
inhibitors of autophagy or the UPS
included during the last 48 h. 3MA, 3-
methyladenine; Baf, bafilomycin; Epo,
epoxomicin; MG, MG132; Veh,
vehicle. The 2DOX control lane
represents the amount of HA–TDP-43
present at the 72-h washout point
without expression having been
induced (‘leakage’). All lanes for each
construct are from the same blot,
spliced as shown. (B) Western blot of
LC3 levels after short treatments with
the autophagy inhibitors 3MA and
bafilomycin showing LC3-I and II
accumulation with 3MA and LC3-II
accumulation with bafilomycin.
(C) The relative HA–TDP-43
remaining in stable HEK293 cells
subjected to DOX pulse–chase with
activators of autophagy included
during the last 24 h of the 48-h chase
period. LiCl, lithium chloride; Rapa,
rapamycin; Tre, trehalose; Veh,
vehicle. The bars represent
means6s.e.m. *P#0.05, **P#0.01,
***P#0.001 between vehicle and
inhibitor-treated cells (two-way
ANOVA, Bonferroni post-test).












To examine more sensitively the conditions under
which ubiquitylated TDP-43 accumulates, we performed
co-immunoprecipitation after treatment with 3MA or MG132,
under native or denaturing conditions (Fig. 4B). In HEK293
HA–TDP-43 WT stable lines transfected with FLAG-tagged
ubiquitin (FLAG–Ub) and then induced with 1 mg/ml DOX
alone, immunoprecipitation with anti-HA antibody yielded a
small amount of FLAG–Ub, which ran as high-molecular-weight
smears (.100 kDa). Induction with DOX plus 3MA for 24 h
resulted in a small increase in the co-immunoprecipitation of
FLAG–Ub by HA–TDP-43 WT, whereas treatment with MG132
for 24 h gave a more striking increase. This finding, which arose
under non-denaturing immunoprecipitation conditions that
preserve protein complexes, could reflect the formation of
complexes containing HA–TDP-43 and ubiquitylated molecules,
rather than direct ubiquitylation of HA–TDP-43. Indeed, using
Fig. 4. See next page for legend.












denaturing conditions (in which the lysate was boiled with 0.5%
SDS to denature non-covalent interactions) a direct FLAG–Ub
interaction with HA–TDP-43 was observed following MG132
treatment but not under basal or 3MA-treated conditions.
These findings indicate that ubiquitylated TDP-43 accumulates
predominantly when the UPS is blocked.
TDP-43 aggregates in human ALS and FTD were initially
characterised as non-amyloid (Cairns et al., 2007); however,
recent studies have found TDP-43 aggregates to be amyloid in at
least a subset of cases (Bigio et al., 2013; Robinson et al., 2013).
We used thioflavin T staining to determine whether the TDP-43
aggregates induced by UPS inhibition were amyloid. UPS
inhibition induced the formation of multiple small amyloid
aggregates, which were sometimes studded within TDP-43-
positive macroaggregates; however, the TDP-43 macroaggregates
themselves were negative for thioflavin T (Fig. 4C). These
findings suggest that the macroaggregates are amorphous and
non-amyloid.
We next investigated the relationship between macroaggregates
detected by immunocytochemistry and detergent-insoluble species
on western blot. Insoluble high-molecular-weight TDP-43 and
insoluble fragmented TDP-43 have been described by Neumann
and colleagues as hallmark features of ALS and FTD (Neumann
et al., 2006). The sequential biochemical fractionation of TDP-43
proteins (generated by a 48-h induction of stable SH-SY5Y cells
with 1 mg/ml DOX) demonstrated that, under basal conditions,
HA-tagged wild-type or DNLS TDP-43 showed a similar
biochemical profile to endogenous TDP-43, with a small
proportion (7–21%) soluble in the low-salt fraction, the majority
of the protein in the Triton X-100-soluble fraction (72–89%) and a
minority of the protein soluble only in sarkosyl or urea (4–11%)
(Fig. 4D,E). The HA-tagged CTF TDP-43 that was used in this
study was almost completely soluble in low-salt and Triton X-100
fractions (.99%). Given its low expression levels, lack of
aggregate formation and high basal solubility, the solubility of
HA–TDP-43 CTF was not investigated further.
Using a simplified solubility protocol, previously validated to
isolate insoluble aggregated TDP-43 (Winton et al., 2008), we
analysed the effect of the inhibition of the UPS or autophagy on
the solubility of wild-type and DNLS TDP-43 (Fig. 4F,G). As for
the immunocytochemical experiments, TDP-43 expression in
stable SH-SY5Y cells was induced with 1 mg/ml DOX in the
presence of inhibitors of autophagy or the UPS for 48 h. The
effect of UPS inhibitors on total TDP-43 levels (lysate) was more
subtle than that shown in Fig. 3A, a result that is likely due to the
differing experimental paradigm – the application of inhibitors
during washout in Fig. 3A versus the application of inhibitors
with continued overexpression in Fig. 4F,G. Owing to the low
proportion of cells forming aggregates, we could not detect an
increase in TDP-43 in the insoluble fraction under conditions
which yielded immuno-detectable macroaggregates. However,
combined UPS and autophagy inhibition (by treatment with 3MA
and MG132) was shown to increase the level of insoluble high-
molecular-weight (oligomeric) TDP-43, indicating that these
species might be regulated by autophagy. Also of note, even
under experimental conditions where TDP-43 appears diffuse by
immunocytochemistry (Veh, 3MA, Baf) a significant amount of
monomeric TDP-43 was insoluble in RIPA buffer.
TDP-43 aggregates induced by UPS inhibition or dual inhibition of the
UPS and autophagy resemble those seen in human disease
We next characterised TDP-43 macroaggregates in terms of their
labelling by molecules that target them for degradation. Given
that dual inhibition of the UPS and autophagy increased the levels
of insoluble TDP-43 and enhanced macroaggregation more than
UPS inhibition alone, we compared the labelling of aggregates
induced by dual inhibition with the labelling of those induced by
UPS inhibition alone.
We first used untreated SH-SY5Y cells to characterise the
basal pattern of staining of the degradation adaptor proteins
ubiquilin-1 and -2 (UBQLN) and p62 (two of which, UBQLN2
and p62, are seen in aggregates in human ALS and FTD), and
polyubiquitin chains with different internal lysine linkages (K48
and K63) (Fig. 5A). These adaptors were localised diffusely in
untreated cells but colocalised with aggregates of wild-type
(Fig. 5B,C) or DNLS TDP-43 (Fig. 5D,E) that had been induced
with 1 mg/ml DOX plus either MG132 with 3MA or MG132
alone. Although 3MA enhanced the recruitment of HA–TDP-43
WT to perinuclear aggregates induced by MG132 treatment
(Fig. 5, intensity plots), it did not alter the labelling profile of the
aggregates.
TDP-43 macroaggregates are cleared upon the restoration of UPS
function
We next sought to specifically investigate the handling of
insoluble TDP-43. We used 1 mg/ml DOX plus MG132, which
acts reversibly, to induce the formation of insoluble TDP-43 WT
or DNLS cellular aggregates and then we followed the fate of
those aggregates after washout of MG132. DOX was maintained
in the medium at a concentration of 1 mg/ml during washout to
Fig. 4. Inhibiton of the UPS, but not autophagy, induces the formation
of detergent-resistant cytoplasmic aggregates of TDP-43.
(A) Immunocytochemical analysis of stable SH-SY5Y lines induced to
express HA–TDP-43 constructs by a 48-h induction with DOX in the
presence of various inhibitors of the UPS or autophagy. When used alone,
UPS inhibitors, but not autophagy inhibitors, induced the formation of
ubiquitin (Ub)-positive TDP-43 macroaggregates (arrowheads). Scale bar:
10 mm. (B) Immunoprecipitation of HA–TDP-43 WT from HEK293 stable
lines transfected with FLAG–Ub then induced with 1 mg/ml DOX alone or
together with 3MA or MG132 for 24 h. Under non-denaturing conditions that
preserve complexes (left) HA–TDP-43 WT co-immunoprecipitated with an
increased amount of FLAG–Ub (smear .100 kDa) under treatment with 3MA
and a greater amount again with MG132. Immunoprecipitation of denatured
lysate (right) showed that HA–TDP-43 that was directly and covalently linked
to FLAG–Ub only accumulated following MG132 treatment. IB, immunoblot.
(C) TDP-43 aggregates are non-amyloid. Stable SH-SY5Y lines were
induced to express HA–TDP-43 constructs by a 48-h induction with DOX in
the absence or presence of MG132. In MG132-treated cells, thioflavin T
staining detected amyloid aggregates that were independent of
macroaggregates of HA–TDP-43 (dashed lines). MG132 treatment of parent
SH-SY5Y cells induced macroaggregates (dashed line) with low levels of
endogenous (Endo) TDP-43, likely owing to autoregulation of TDP-43 protein
levels. Scale bar: 10 mm. (D,E) Four-step fractionation of stable SH-SY5Y
lines induced to express HA–TDP-43 constructs by a 48-h induction with
DOX. WT, upper white arrowhead; DNLS, middle black arrowhead; CTF,
lower black arrowhead. The CTF was largely soluble in the low-salt (LS)
fraction (TX, Triton X-100; Sark, sarkosyl). Note that the pellets from each
step were resuspended in different volumes to ensure the detection of all
fractions. Relative concentrations of the fractions are: Lys, 1; LS, 1; TX, 0.5;
Sark, 3.33; urea 2.5. The bars represent means6s.e.m. (F,G) Solubility
fractionation of the cells treated as in A, showing the lysate (L), RIPA-soluble
(R) and urea-soluble (U) fractions of HA–TDP-43 WT (F) and DNLS (G). Urea
fractions are concentrated 10-fold. Combined treatment with UPS and
autophagy inhibitors ({) increased the amount of insoluble high-molecular-
weight (HMW) TDP-43, particularly for TDP-43 DNLS (G). 3MA, 3-
methyladenine; Baf, bafilomycin; Epox, epoxomicin; MG, MG132;
Veh, vehicle.












Fig. 5. TDP-43 aggregates induced by UPS inhibition or dual inhibition of the UPS and autophagy resemble those seen in human disease.
(A) Immunocytochemical analysis of untreated SH-SY5Y cells showing the diffuse localisation of the degradation pathway proteins ubiquilin-1 or -2 (UBQLN)
and p62, and K48- and K63-linked forms of ubiquitin (Ub). Scale bar: 25 mm. (B–E) Immunocytochemical analysis of stable SH-SY5Y lines induced to express
HA–TDP-43 by a 48-h induction with DOX in the presence of UPS inhibition or combined inhibition of the UPS and autophagy. (B) HA–TDP-43 WT formed
cytoplasmic macroaggregates (arrowheads) following treatment with DOX plus the proteasome inhibitor MG132 in stable SH-SY5Y cells. These aggregates
were positive for post-translational modifications (PTMs) including K48- and K63-linked ubiquitin, ubiquilin-1 and -2 and p62. (C) Combined treatment with DOX,
MG132 and the autophagy inhibitor 3MA enhanced the recruitment of HA–TDP-43 WT to macroaggregates, which were positive for the same markers as with
MG132 treatment alone. (D) HA–TDP-43 DNLS also formed cytoplasmic aggregates following a 48-h treatment with DOX plus MG132 in stable SH-SY5Y cells.
As was seen for HA–TDP-43 WT, these aggregates were positive for K48- and K63-linked ubiquitin, ubiquilin-1 and -2 and p62. (E) Combined treatment with
DOX plus MG132 and 3MA did not markedly alter the recruitment of HA–TDP-43 DNLS to macroaggregates. Arrows on the bottom row of images in B–E
represent the section taken for the intensity profiles shown below the images. Scale bars: 10 mm.












ensure that our findings reflected TDP-43 aggregate handling in
the face of continued expression of TDP-43. End-point imaging
showed that for both WT (Fig. 6A) and DNLS TDP-43 (Fig. 6B),
cells given a 48-h washout period after MG132 treatment were
devoid of TDP-43-positive and p62-positive aggregates, in stark
contrast to cells fixed directly after the MG132 treatment. The
biochemical correlate of this was a reduction in detergent-resistant
high-molecular-weight TDP-43 following MG132 washout
(Fig. 6C,D). These findings might indicate that there is selective
survival of cells without TDP-43 aggregates or that aggregated
TDP-43 is either refolded or degraded following restoration of UPS
function.
We therefore examined the clearance of aggregates in live cells,
using stable SH-SY5Y cells transfected with EGFP-tagged
TDP-43. We verified that the replacement of the N-terminal
HA-tag with EGFP did not alter the timecourse of TDP-43
degradation by performing doxycycline pulse-chase experiments
(Fig. 6E, t1/2; EGFP–TDP WT, 29.3 h; HA–TDP WT, 29.2 h). We
also verified that EGFP-tagged TDP-43 was functional,
as evidenced by its ability to downregulate endogenous TDP-43
(Ayala et al., 2011) (Fig. 6F). We next performed live-cell imaging
of cells with MG132-induced aggregates of EGFP–TDP-43 DNLS,
which indicated that most aggregate-laden cells died over a 15-h
washout period (69.3%65.6) and also that aggregates were rapidly
cleared by the surviving cells (Fig. 6G; supplementary material
Movie 1). Owing to the low fluorescence intensity of EGFP–TDP
WT aggregates, their clearance could not readily be measured in
living cells.
TDP-43 aggregate clearance is due to the enhanced mobility of
lower-order aggregated species, rather than the clearance of
macroaggregated TDP-43
Previous work on other aggregate-prone proteins indicates that
some aggregates (e.g. juxta-nuclear quality control aggregates,
JUNQ) are mobile, readily exchange with the diffuse protein pool
and can be cleared by the UPS (Ben-Gedalya et al., 2011;
Fig. 6. TDP-43 macroaggregates are
cleared upon the restoration of UPS
function. Immunocytochemical
analysis of stable SH-SY5Y lines
induced to form HA–TDP-43 WT (A) or
HA–TDP-43 DNLS (B) aggregates
(arrowheads) by a 48 h induction with
DOX plus MG132 then fixed or
subjected to MG132 washout (wo) after
which the cells were left for a further 48
h. Scale bar: 10 mm.
(C,D) Solubility fractionation of stable
HA–TDP-43 WT (C) or HA–TDP-43
DNLS (D) SH-SY5Y lines either
induced with DOX, induced to form
aggregates by 48-h treatment with DOX
plus MG132 or induced to form
aggregates then subjected to MG132
washout after which the cells were left
for a further 48 h. Lysate (L), RIPA-
soluble (R) and urea-soluble
(U) fractions are shown. Urea fractions
are concentrated 10-fold. MG132 (*)
increased the proportion of high-
molecular-weight insoluble TDP-43
(HMW) and this was reversible upon
MG132 washout (48 h). (E) Validation
that EGFP-tagged TDP-43 WT is
degraded over the same timecourse as
HA–TDP-43 WT in stable SH-SY5Y
cells (t1/2; HA–TDP-43 WT, 29.2 h;
EGFP–TDP-43 WT, 29.3 h).
(F) Validation that both HA- and EGFP-
tagged TDP-43 WT (grey arrowheads)
are functional and can regulate the level
of endogenous TDP-43 (black
arrowhead) in stable SH-SY5Y cells.
Black bars represent endogenous
TDP-43 and grey bars represent
exogenous TDP-43. UT, untransfected.
(G) Live-cell imaging of stable SH-
SY5Y lines induced to form EGFP–
TDP-43 DNLS aggregates by 48 h
induction with DOX plus MG132 then
subjected to washout and followed for a
further 15 h. In cells that cleared
aggregates, the aggregates
fragmented before clearance. Scale
bar: 10 mm.












Kaganovich et al., 2008). To determine whether this was true
for TDP-43, we performed fluorescence recovery after
photobleaching (FRAP) on diffuse and macroaggregated EGFP–
TDP-43 DNLS (Fig. 7A) in stable SH-SY5Y cells. FRAP
measures both the proportion of a given protein pool that is
mobile and the rate of mobility by examining the migration of
fluorescent proteins back into a region that has been bleached of
fluorescence.
We examined cells that were induced to express EGFP–TDP-
43 using 1 mg/ml DOX alone, cells induced to form aggregates
with 1 mg/ml DOX plus MG132, and cells induced to form
aggregates then washed out and left in fresh medium containing
1 mg/ml DOX without MG132 for 8–10 h. Firstly, by bleaching
diffuse cytosolic EGFP–TDP-43 DNLS we found that the
proportion of diffuse TDP-43 protein that was mobile was
reduced by inhibition of the UPS, both in cells devoid of
aggregates and, more strikingly, in cells that contained large
aggregates (Fig. 7B,C; percentage of TDP-43 that was mobile:
DOX only, 69%60.9; MG132 without aggregates, 64%61,
P#0.01; MG132 with aggregates, 48%61.6, P#0.001; 6s.e.m.).
Furthermore, we found that the TDP-43 within the aggregates
was almost completely immobile, with the bleached portions of
the aggregates remaining dark for the duration of FRAP imaging
and not visibly exchanging with the diffuse pool (Fig. 7A–C;
percentage of TDP-43 that was mobile: 2.7%60.1, P#0.001). At
8–10 h after the washout of MG132, there was a significant
increase in the proportion of diffuse TDP-43 that was mobile
in cells still containing large aggregates, suggesting there
was mobilisation or clearance of previously immobile species
(percentage of TDP that was mobile: 48%61.6 before and
61%60.7 after washout, P#0.001). However, direct bleaching of
macroaggregated TDP-43 showed that this species was not
mobilised, as it showed no increase in the mobile fraction after
washout.
Next, we examined the rate of fluorescence recovery (the
speed of molecular movement) for mobile species of TDP-43
protein (Fig. 7D). Diffuse TDP-43 in vehicle-treated cells
showed rapid recovery (t1/253.4 s). Diffuse TDP-43 in cells
exposed to UPS inhibition but without aggregates showed a
similar rate of recovery (t1/253.6 s), whereas TDP-43 in cells
with aggregates showed significantly slower recovery (t1/256.9 s).
A decrease in the fluorescence recovery rate indicates increased
binding or increased size of the TDP-43 particle, consistent with
oligomerisation of TDP-43. At 8–10 h after the washout of
MG132, there was an increase in the rate of recovery of diffuse
TDP-43 in cells with large aggregates (t1/256.9 s before versus
4.0 s after washout), suggesting that there had been removal or
dissociation of slow-moving species.
Fig. 7. TDP-43 aggregate clearance is due to enhanced mobility of lower-order aggregated species, rather than mobility of macroaggregated TDP-43.
(A) Confocal images acquired during FRAP. EGFP–TDP-43-DNLS showed rapid fluorescence recovery for diffuse cytosolic forms (Cyt TDP) but no recovery
for aggregated forms (Agg TDP), indicating that macroaggregated TDP-43 is immobile and unlikely to readily exchange with the diffuse pool. The white dashed
line encloses the bleached area. Scale bar: 10 mm. (B) FRAP recovery curves, with bleaching at t50 and 100% representing the pre-bleach fluorescence
intensity. The fraction of cytosolic TDP-43 that was mobile was slightly decreased in cells that were treated with MG132 (MG) but were devoid of aggregates
(Cyt TDP 2Agg) and was greatly decreased in cells containing an aggregate (Cyt TDP +Agg). (C) The fraction of TDP-43 that was mobile under various
conditions. The decrease in the mobile fraction in cells treated with MG132 and containing an aggregate (Cyt TDP +Agg) was rescued 8–10 h after washout
(wash). There was no mobilisation of macroaggregated TDP-43 upon washout. (D) The rate of FRAP recovery [given as K5ln(2)/t1/2] for mobile species under
various conditions. The FRAP rate was significantly decreased in cells that were treated with MG132 and contained an aggregate (Cyt TDP +Agg), which
was reversed after washout. The bars represent means6s.e.m.; n.s., not significant. **P#0.01, ***P#0.001 between control and treated cells or as shown (one-
way ANOVA, Bonferroni post-test).












TDP-43 aggregate clearance requires autophagy
Our findings suggested that during washout, slow-moving and
immobile species were either resolved into mobile or faster-
moving species, or were removed directly. Oligomeric or
microaggregated species cannot be cleared directly by the
UPS, and their clearance might require aggregate autophagy or
‘aggrephagy’ (Lamark and Johansen, 2012; Øverbye et al.,
2007). Therefore, in order to test whether aggregate clearance
involved autophagy, we first determined whether cells with
TDP-43 aggregates contained autophagosomes, the double-
membraned effectors of autophagy. Cells that were transfected
with the autophagosome marker mCherry–GFP–LC3 showed a
significant increase in the number of autophagosomes (GFP-
positive puncta) in cells induced to form TDP-43 aggregates
(1 mg/ml DOX plus MG132) compared to controls (Fig. 8A,B;
autophagosomes per cell: WT, 3668 MG132 versus 261 DOX,
P#0.01; DNLS, 3169 MG132 versus 662 DOX, P#0.05;
6s.e.m.).
We next examined the impact of autophagy inhibition on
aggregate clearance, by performing live imaging. Cells were
induced to form aggregates of EGFP–TDP-43 DNLS using 1 mg/
ml of DOX plus MG132, and inhibitors of autophagy were added
during the washout period (Fig. 8C). As discussed, the majority
of cells with aggregates died over the course of imaging.
Fig. 8. TDP-43 aggregate clearance requires autophagy. (A) Autophagosomes in cells containing TDP-43 aggregates. Stable SH-SY5Y lines were
transfected with mCherry–GFP–LC3 and then induced to form HA–TDP-43 WT or DNLS aggregates (arrowheads) by a 48-h induction with DOX plus MG132.
(B) Quantification of the number of GFP–LC3-positive autophagosomes per cell in cells treated as in A. The bars represent means6s.e.m. *P#0.05, **P#0.01
between control and treated cells (unpaired Student’s t-tests with Welch’s correction). (C) Live-cell imaging of stable SH-SY5Y lines that were induced to
form EGFP–TDP-43 DNLS aggregates (arrowheads) by a 48-h induction with DOX plus MG132, then subjected to washout and followed for a further 15 h in the
presence of bafilomycin (Baf). Aggregates fragmented but were not cleared. (D) Regression analysis of the relationship between the aggregate load
(integrated intensity of aggregate) and clearance time in the presence or absence of autophagy inhibitors during washout (wo) [3MA, 3-methyladenine; Baf,
bafilomycin; Veh, vehicle; Pearson’s r50.72 (Veh wo); 0.70 (3MA wo); 0.23 (Baf wo)]. Small aggregates were cleared rapidly in the absence, but not presence,
of autophagy inhibitors. In Baf wo cells a distinct population of aggregates that were not cleared by the end of imaging (scored as 15 h) can be seen
(dashed line). (E) Relative rates of clearance of EGFP–TDP-43 DNLS aggregates according to the slopes of the lines shown in D. Note that the slope for Baf wo
includes the ‘non-clearing’ population. The results are not significant by one-way ANOVA. Scale bars: 10 mm.












Aggregate-containing cells that died had significantly greater
aggregate load than those that lived (average aggregate integrated
intensity was 732861661, versus 19616522 in cells that lived,
P#0.01, Student’s t-test with Welch’s correction; 6s.e.m.). For
cells that survived the period of imaging, we plotted the
relationship between the load of aggregated protein and the rate
of clearance from the cell (Fig. 8D). In the absence of autophagy
inhibitors, we found a positive linear relationship between the
aggregated protein load and the time taken for clearance (Fig. 8D,
Veh). When autophagy inhibitors were present, macroaggregates
were still disassembled into smaller discrete aggregates, suggesting
an autophagy-independent disaggregation step (Fig. 8D, Baf;
supplementary material Movie 2). However, these aggregates then
persisted in the cells. The slope of the line relating initial aggregate
load with clearance time therefore flattened in the presence of
autophagy inhibitors (Fig. 8D,E, relative slope 3MA, 0.74; Baf,
0.15). The presence of aggregates that completely failed to be
cleared over the 15-h timecourse in the presence of bafilomycin,
regardless of their size (Fig. 8D, dashed line), showed that
aggregate clearance was strongly dependent on autophagy.
DISCUSSION
A number of genetic causes of ALS and FTD converge upon the
pathways involved in TDP-43 protein degradation. Mutations in
TDP-43 itself confer resistance to degradation (Kabashi et al.,
2008; Rutherford et al., 2008; Sreedharan et al., 2008), whereas
mutations in p62, ubiquilin-2 and VCP (Deng et al., 2011; Fecto
et al., 2011; Watts et al., 2004) disrupt the autophagy and UPS
pathways, both of which are involved in the degradation of TDP-
43. However, the relative contribution of these pathways to the
maintenance of TDP-43 proteostasis has been unclear. Previous
studies provide conflicting evidence, finding either that wild-type
TDP-43 is degraded predominantly by the UPS (Caccamo et al.,
2009; Crippa et al., 2010; Wang et al., 2010; Zhang et al., 2010)
or predominantly by autophagy (Urushitani et al., 2010), and
none have specifically examined the degradation of aggregated
TDP-43. Here, we demonstrate that the degradation of the soluble
complement of full-length TDP-43 is mediated primarily by the
UPS, whereas aggregated TDP-43 requires autophagic clearance.
As is the case for many proteins, cellular TDP-43 can exist as
several different species with variable microscopical appearance
and variable solubility and mobility profiles. In this study,
we find evidence for soluble monomeric, soluble oligomeric,
insoluble microaggregated and insoluble macroaggregated forms
of TDP-43. Soluble monomer appears diffuse, is detergent-
soluble and shows fast FRAP. Soluble oligomer also appears
diffuse and is detergent-soluble but shows slow FRAP. Insoluble
microaggregates also appear diffuse but are detergent-insoluble
and immobile in FRAP experiments. Insoluble macroaggregates
are evident only in UPS-inhibitor-treated cells, as immuno-
detectable entities composed of detergent-insoluble high-
molecular-weight species that show no FRAP mobility.
Our proposed model for the existence of these species under
different conditions is outlined in Fig. 9. Normally, in the presence
Fig. 9. A working model for the differential
degradation of TDP-43 species. Upper panel;
under normal conditions, TDP-43 exists as several
different species with variable appearance (diffuse
or macroaggregated), solubility and mobility (fast
or slow). When the UPS is functional, the removal
of soluble monomer drives the equilibrium in
favour of small soluble species and precludes the
formation of macroaggregates. By contrast, UPS
blockade drives the accumulation of oligomers and
insoluble species, where insoluble species include
‘microaggregated’ and macroaggregated TDP-43;
microaggregates appear visually diffuse but are
immobile in FRAP experiments and
macroaggregates are visible by
immunofluorescence and immobile. Lower panel;
a working model for TDP-43 clearance after
macroaggregate formation. Under normal
conditions macroaggregates are cleared by the
induction of autophagy, which removes oligomeric
and microaggregated species. Monomer is cleared
by the UPS. Autophagy blockade prevents the
removal of oligomer and microaggregates,
although the fragmentation of macroaggregates
still occurs.












of a functional UPS, the removal of soluble monomer serves to drive
the equilibrium sufficiently to the left to favour small soluble species
and to preclude the formation of macroaggregates. Therefore,
in both cell culture models and tissue from human controls, only
a small proportion of TDP-43 is detergent-insoluble basally
(Neumann et al., 2006). By contrast, UPS blockade drives the
accumulation of slow-moving oligomers and insoluble immobile
TDP-43 species, which can appear diffuse (microaggregates)
or clearly aggregated (macroaggregates). The clearance of
macroaggregates involves fragmentation into smaller pieces,
which is autophagy independent, and then the removal of lower-
order species by autophagy. Oligomers, microaggregates or both can
be substrates for autophagy, as autophagy blockade favours the
continued existence of fragmented macroaggregates.
It has previously been shown that inhibition of the UPS can
induce aggregates of full-length TDP-43 (Kim et al., 2012; van
Eersel et al., 2011). However, to our knowledge, full-length TDP-
43 has never been shown to aggregate in cells under conditions
of autophagy inhibition alone. Similarly, ALS with TDP-43
proteinopathy can be modelled in vivo in mice by knockout of a
proteasome subunit (Rpt3, also called PSMC4) but not by
knockout of a key molecule in autophagy induction, Atg7
(Tashiro et al., 2012). This supports a model whereby the levels
of soluble TDP-43 are predominantly regulated by the UPS and
the accumulation of these species can lead to the ‘nucleation’ of
aggregates. Thus, the impairment of proteasomal degradation
in cell lines recapitulates the TDP-43 accumulation, aggregation
and inclusion formation that occurs in vivo. The subsequent
impairment of autophagy prevents the removal of aggregated
TDP-43.
There has been fierce scientific debate amongst
neurodegeneration researchers as to whether visible protein
macroaggregates are the ‘toxic species’, are protective or are
epiphenomena associated with, but not causative of, disease.
The emerging consensus is that macroaggregates might be a
‘sink’ for the true toxic species, which are predominantly lower-
order oligomers with greater mobility and surface area, and
thus have enhanced potential for aberrant interactions (Caughey
and Lansbury, 2003; Haass and Selkoe, 2007). Macroaggregates
can, however, act as a surrogate to assess the levels of
these oligomeric species. It is likely that the large TDP-43
macroaggregates that we report here are ‘aggresomes’, a
conglomeration of smaller aggregates that are actively
transported along microtubules to perinuclear regions (Kopito,
2000). Aggresome formation is dependent on several molecules
whose genomic mutation is linked to ALS and FTD, including
VCP, p62 and dynein–dynactin (Johnston et al., 2002; Puls et al.,
2003; Seibenhener et al., 2004), as well as the ubiquilin-2-related
molecule, ubiquilin-1 (Heir et al., 2006). Aggresomes are thought
not only to sequester smaller aggregates to minimise their toxicity
but also to coordinate aggregate removal by autophagy, a
process known as ‘aggrephagy’ (Lamark and Johansen, 2012).
Aggrephagy is therefore emerging as a key target for drug
discovery in ALS and FTD (Thomas et al., 2013).
In this study, we show for the first time that full-length TDP-43
macroaggregates are labelled by both K48- and K63-linked
polyubiquitin chains. Ubiquitin chains with these different
linkages are thought to direct proteins towards different fates
owing to the specificity of binding partners for specific linkages.
K48-linked polyubiquitin chains are associated with UPS
degradation (Xu et al., 2009). By contrast, K63-linked chains
are associated with an autophagic fate. The autophagic adaptor
protein p62 is selective for K63-linked chains (Seibenhener et al.,
2004) and acts to recruit LC3-positive autophagosomes (Pankiv
et al., 2007). Ubiquilin-2 can bind proteins labelled with either
type of ubiquitin chain linkage (Rothenberg et al., 2010). The
presence of both types of chain on TDP-43 aggregates could
be consistent with a model in which K48–ubiquitin-labelled
substrates cannot be degraded by the UPS and are subsequently
labelled with K63–ubiquitin for aggrephagy (Yamamoto and
Simonsen, 2011).
An autophagic mode of clearance of aggregated TDP-43
echoes that of other neurodegenerative disease proteins. Soluble
fragments of wild-type huntingtin are degraded proteasomally but
aggregated expanded-repeat fragments are not accessible to the
proteasome and are degraded by autophagy (Qin et al., 2003).
Mutant androgen receptor, the protein that causes spinal and
bulbar muscular atrophy (SBMA), is toxic to flies and this
toxicity is enhanced when autophagy is blocked together with the
UPS (Pandey et al., 2007).
Although autophagy is inducible in response to a heavy
burden of aggregated proteins (Ding et al., 2007; Iwata et al.,
2005; Laussmann et al., 2011; Rideout et al., 2004), in our
model autophagy induction was unable to clear TDP-43
macroaggregates in the face of continued UPS inhibition. Dual
treatment with inhibitors of the UPS and autophagy revealed that
autophagy had been serving to reduce the aggregated TDP-43
burden caused by UPS inhibition alone. However, complete
aggregate clearance only occurred after washout of the UPS
inhibitor, indicating that autophagy could not fully compensate
for UPS impairment. Although we used low-dose chronic UPS
inhibition to attempt to more closely mimic the slow degenerative
process in humans, the degree of UPS impairment is likely to far
exceed that which could be caused by aging or by the genetic
mutations detected in some ALS and FTD cases. Therefore, the
activation of autophagy remains a promising therapeutic
approach to treating ALS and FTD in humans. Indeed,
autophagy activation has been shown to clear a-synuclein
inclusions in primary postmitotic neurons even when there is
continued moderate inhibition of the UPS using lactacystin
(Rideout et al., 2004). Excitingly, in a mouse model of FTD based
on TDP-43 overexpression, rapamycin [an inhibitor of mTOR,
which therefore activates (de-represses) autophagy] was used to
induce the clearance of TDP-43, increasing motor neuron survival
and motor function (Wang et al., 2012).
As we age, the efficiency of both the UPS and autophagy decline
(Gamerdinger et al., 2009; Tydlacka et al., 2008; Zhou et al., 2003).
However, in aged individuals without ALS or FTD, TDP-43
aggregates do not commonly accumulate. In people affected by
ALS and FTD, TDP-43 inclusions form and remain at the end of
life, leading us to speculate that, in addition to normal aging, there
is secondary impairment of the UPS or autophagy, promoting
the accumulation of misfolded species and preventing their
removal. Augmenting UPS function could help to restore TDP-
43 proteostasis and, where UPS impairment persists, the activation
of autophagy might reduce the aggregated TDP-43 protein burden.
Therefore, identifying molecules that selectively enhance each of
these processes, and that can be used in combination to reduce
TDP-43 accumulation, is a valid therapeutic strategy.
MATERIALS AND METHODS
Plasmids
Constructs are shown schematically in Fig. 1A. These constructs allow
doxycycline-inducible expression of tagged (HA or EGFP) TDP-43 wild












type (WT), nuclear localisation sequence-deleted [DNLS (D82–98)] or C-
terminal fragment [CTF (181–414)]. All constructs were generated by
Gateway cloning (Invitrogen Life Technologies, Carlsbad, CA). AttB-
flanked PCR products were subcloned into pDONR221 using BP clonase
II, then into pDEST30 using LR clonase II, according to the
manufacturer’s instructions (Invitrogen Life Technologies). N-terminal
HA.11-tagged TDP-43 WT, DNLS and CTF were amplified from
existing constructs (Nishimura et al., 2010). N-terminal EGFP-tagged
TDP-43 WT was first generated using pEGFP-C1 (XhoI/BamHI) then
subcloned into Gateway. EGFP-tagged TDP-43 DNLS was generated by
site-directed mutagenesis of the WT construct in pDONR (QuikChange
II, Stratagene). Primer sequences are available on request.
All constructs were verified in-house by DNA sequencing using Big-
Dye Terminator v1.1 (Invitrogen Life Technologies, Paisley, UK) on an
ABI3130 genetic analyser (Applied Biosystems Pty Ltd, Warrington,
UK). Sequence chromatograms were analysed using Geneious v5.4.6
(Biomatters, Auckland, NZ). All primers were obtained from Sigma-
Aldrich (Dorset, UK). mCherry–GFP–LC3 plasmid (Pankiv et al., 2007)
was kindly supplied by Terje Johansen (University of Tromsø, Norway).
FLAG–Ub plasmid (Tan et al., 2008) was a kind gift of Lim Kah-Leong
(National University of Singapore).
UPS and autophagy modifying drugs
3MA (used at 10 mM), bafilomycin (400 nM) and lithium chloride
(10 mM) were purchased from Acros Organics (Geel, Belgium). MG132
(0.5 mM), epoxomicin (100 nM) and rapamycin (0.2 mg/ml) were
purchased from Cayman Chemicals (Cambridge, UK). Trehalose
(100 mM) was purchased from Sigma-Aldrich.
Mammalian cell line culture, transfection, plating and induction
Stable tetracycline-inducible (Tet-ON) clonal cell lines were generated in
human neuroblastoma SH-SY5Y cells (CRL-2266; ATCC, Middlesex,
UK) and human embryonic kidney HEK293 (T-REx HEK293, #R710-07,
Invitrogen Life Technologies), using the T-REx system. Briefly, stable
clonal lines transfected with pcDNA6/TR (encoding a constitutively
expressed Tet-repressor protein) were transfected with pDEST30-TDP-
43 constructs using Lipofectamine 2000, selected using 600 mg/ml
geneticin and clonally isolated.
SH-SY5Y cells were maintained in DMEM/F12 plus Glutamax,
supplemented with 10% fetal bovine serum (FBS) (Tet-free, S0115T,
BioChrom AG, Berlin, Germany), 100 U/ml penicillin and 100 mg/ml
streptomycin. HEK293 cells (stable Tet-ON) were maintained in DMEM plus
Glutamax, supplemented with 10% FBS (Tet-free), 100 U/ml penicillin and
100 mg/ml streptomycin. All cells were maintained at 37 C̊, under 5% CO2.
Transient transfection of mCherry–GFP–LC3 into stable SH-SY5Y
lines was performed using Lipofectamine 2000, as per the manufacturer’s
instructions. Transient transfection of FLAG–Ub into stable HEK293
lines was performed using Fugene HD (Promega, Southampton, UK) as
per the manufacturer’s instructions. For experimental analyses, SH-SY5Y
lines were plated at 75,000 cells/cm2, HEK293 lines were plated at
25,000 cells/cm2 and TDP-43 expression was induced using 1 mg/ml
DOX, unless otherwise stated. All reagents were purchased from
Invitrogen Life Technologies unless otherwise stated.
Immunofluorescence and imaging
For immunofluorescence analyses, SH-SY5Y lines were plated onto
untreated 13-mm coverslips (1.5 thickness). HEK293 lines were plated
onto poly-D-lysine-treated coverslips. After treatment, cells were fixed in
4% paraformaldehyde (PFA, VWR International Ltd, Leicestershire, UK)
for 10 min and rinsed with phosphate-buffered saline (PBS). The cells
were incubated with primary antibody overnight at 4 C̊, then with
fluorescent secondary antibodies for 6 h at room temperature, each
diluted in PBS with 0.2% Triton X-100 and 1% serum (goat or donkey as
appropriate). For thioflavin T staining, cells were stained for 10 min with
freshly prepared and filtered 0.1% thioflavin T (Acros Organics) in PBS
and rinsed. After immunodetection, the coverslips were mounted onto
slides using fluorescence mounting medium (Dako, Carpenteria, CA) and
left to harden overnight.
The antibodies used for immunofluorescence were against TDP-43
(mouse: sc-100871, 1:500, Santa Cruz Biotechnology, Heidelberg,
Germany; rabbit: 1078-2-2-AP, 1:500, ProteinTech Europe,
Manchester, UK), HA.11 (mouse; MMS-101P, 1:1000, Covance,
Leeds, UK: rabbit; #3724, 1:1000, Cell Signaling Technology, Beverly,
MA), p62 (#610833, 1:1000, BD Biosciences, San Jose, CA), ubiquitin
(Z0458, 1:200, Dako UK Ltd, Ely, UK), K48-linked ubiquitin (#05-1307,
1:500, Millipore, Temecula, CA), K63-linked ubiquitin (#05-1308,
1:500, Millipore), ubiquilin-2 (sc-100612, 1:2000, Santa Cruz
Biotechnology; also detects ubiquilin-1 by western bloting). Invitrogen
Life Technologies goat secondary antibodies (Alexa-Fluor-4882anti-
mouse-IgG, A11001; Alexa-Fluor-5682anti-rabbit-IgG, A11011) or
Jackson ImmunoResearch donkey secondary antibody (Alexa-Fluor-
6492anti-mouse-IgG, 715-495-150) were used at 1:500.
Wide-field imaging was performed using a Zeiss Axiovert S100 (Carl
Zeiss Ltd, Hertfordshire, UK) with a 663/NA 1.25 Plan Neofluar oil
immersion objective, fitted with a CoolSnap EZ digital camera
(Photometrics, Tucson, AZ). Confocal images were acquired using a
Leica TCS SP5 confocal laser scanning microscope (Leica Microsystems,
Buckingham, UK) with a663/NA 1.4 Plan Apo oil immersion objective
and a pinhole of 95.6 mm (Airy 1). Images (102461024 pixels) were
acquired at 400 Hz with a line averaging of 8, using Leica LAS-AF
software and 405 nm, 488 nm and 633 nm laser lines.
Line intensity profiles were quantified using the colour profiler plug-in
(Dimiter Prodanov) in ImageJ (version 1.45e, NIH, Bethesda, USA, http://
rsb.info.nih.gov/ij/) on merged RGB images for a representative
experiment. GFP–LC3 autophagosomes were quantified using the
Granularity tool in Metamorph (v. 7.7, Molecular Devices, Wokingham,
UK) and the granules were normalised to the number of transfected cells
by manual counting of GFP-positive cells. 113–622 granules were counted
in 20–50 transfected cells in a representative experiment.
Doxycycline pulse–chase assay
The degradation rates of the various TDP-43 constructs were investigated
by doxycycline (DOX) pulse–chase as described previously (Ravikumar
et al., 2002). Briefly, TDP-43 expression was induced for 24 h using
10 ng/ml DOX to achieve almost maximal expression (Fig. 1D,E). For
washout, the cells were rinsed twice in fresh DOX-free medium. For the
initial characterisation of the degradation rate in HEK293 cells, the
samples were harvested just before DOX washout (0 h) and 24, 48 and
72 h after washout (Fig. 2A). For the validation of degradation rates in
SH-SY5Y cells, samples were harvested 24, 28, 32 and 48 h after
washout (Fig. 2B). To investigate the degradation pathways for TDP-43
in HEK293 cells, samples were harvested just before DOX washout (0 h)
then inhibitors, activators or vehicle controls were added after 24 h of
washout and samples were taken after a further 48 h (Fig. 3A). The cells
were harvested into 16SDS loading buffer [Laemmli buffer (Laemmli,
1970) without Bromophenol Blue or reducing agents] and were boiled
for 10 min before freezing at 220 C̊. Wells treated with MG132,
epoxomicin or bafilomycin were plated at twice the density used for
degradation assays, to reduce toxicity (Bar et al., 2004). Degradation
timecourse data were fitted to a one-phase exponential decay and plotted
using GraphPad Prism 6.02 (GraphPad Software, San Diego, CA).
Quantitative PCR
Total RNA was extracted and DNase-treated using the RNeasy Lipid
Tissue Mini Kit (Qiagen, West Sussex, UK) and cDNA was reverse
transcribed using oligo(dT) primers with SuperScript III First-Strand
Synthesis SuperMix (Invitrogen Life Technologies). Quantitative PCR was
performed using FASTStart SYBR Green Mastermix on a 7900HT Fast
Real-Time PCR System (Applied Biosystems) running SDS v.2.3
software. The primers that were used to detect HA–TDP WT and DNLS
transcripts were 59-TACCCATACGATGTTCCAGATTAC-39 and 59-
GCATGCAGAATTCCTTCTACC-39. HA–TDP CTF transcripts were
quantified using the same HA-specific forward primer with the reverse
primer 59-CCCGTACTGAGAGAAGAACT-39. GAPDH acted as a
reference transcript, using the primers 59-CAGCCTCAAGATCAT-
CAGCA-39 and 59-GGCATGGACTGTGGTCATGAG-39. PCR cycling












conditions were: activation, 10 min at 95 C̊; cycling, 15 s at 95 C̊, 30 s at
60 C̊ and 30 s at 72 C̊ for 40 cycles; followed by the thermal denaturation
protocol. The expression levels of HA–TDP transcripts relative to GAPDH
transcripts (reference), with normalisation to no DOX (control), were
determined using the Pfaffl method (Pfaffl, 2001).
Solubility fractionation
The sequential biochemical fractionation of cellular proteins was
performed as described previously for ALS and FTD brain
homogenates (Sampathu et al., 2006), with several modifications for
cells. Pellets were initially resuspended in low-salt (LS) buffer, and were
sequentially resuspended in the following buffers (volumes are shown
relative to the LS volume): Triton X-100, 200%; sarkosyl, 30%; urea,
40%. Centrifugation was performed at 14,000 rpm for 30 min at 4 C̊. The
myelin flotation buffer step was omitted.
RIPA/urea solubility fractionation was performed as described by
Winton and colleagues (Winton et al., 2008), using centrifugation at
14,000 rpm for 30 min at 4 C̊ and omitting sonication. The final (urea)
pellet was resuspended in 10% of the original lysis volume.
Western blotting and densitometry analysis
Protein concentrations were quantified using the BioRad DC Protein
Assay (BioRad, Hemel Hempstead, UK) and equivalent protein was
loaded for each sample (HEK293, 5 mg; SH-SY5Y, 10 mg). For solubility
experiments, whole-lysate protein was quantified and the equivalent
liquid volume of the soluble and insoluble fractions was loaded. Gels
were transferred onto nitrocellulose using the iBlot (Invitrogen Life
Technologies), stained with Ponceau S and then blocked in TBS with
0.05% Tween-20 (TBS-T) and 5% non-fat dried milk (NFDM, Sigma-
Aldrich) for 30 min. The blots were probed overnight at 4 C̊ with primary
antibody, then for 3 h at room temperature with secondary antibodies (all
in TBS-T plus 1% NFDM). The blots were scanned on the Li-Cor
Odyssey gel scanner (Li-Cor Biotechnology, Cambridge, UK) and were
then reprobed (without stripping) for loading-control proteins using the
same antibody conditions and scanning protocol.
Antibodies used for blotting were against TDP-43 (mouse: sc-100871,
1:1000), HA.11 (#3724, 1:1000), Histone H3 (H0164, 1:10,000, Sigma-
Aldrich), p62 (#610833, 1:1000), GAPDH (G9545, 1:1000, Sigma-
Aldrich), GFP (mouse: sc-9996, 1:1000, Santa Cruz), LC3B (#2775,
1:500, Cell Signaling Technology) and Dylight fluorescent secondary
antibodies (35521, goat anti-mouse-IgG–Dylight-680, 1:5000; 35568,
goat anti-rabbit-IgG–Dylight-700, 1:10,000, Fisher Scientific UK Ltd,
Leicestershire, UK).
The blot images in TIF format were quantified using the gel analyser
tool in ImageJ. Integrated band intensities were normalised to the band
intensities of loading controls and also to relative input for the solubility
assays.
TDP-43 aggregate clearance assays
The clearance of TDP-43 aggregates was assessed by RIPA/urea solubility
fractionation and immunofluorescence (HA-tagged constructs) and live-
cell imaging and fluorescence recovery after photobleaching (FRAP)
(EGFP-tagged constructs). For all aggregate clearance assays, stable SH-
SY5Y TDP-43 WT or DNLS cells were plated at 100,000 cells/cm2 and
were left to recover overnight. TDP-43 expression was induced with DOX
for 24 h and then aggregate formation was induced using DOX with
0.5 mM MG132 for a further 48 h. For washout experiments, the cells were
then washed and left in fresh medium containing DOX without MG132, in
the presence or absence of inhibitors for the stated time periods.
Live-cell imaging
Live imaging was used to assess whether EGFP–TDP-43 DNLS aggregates
were cleared. Stable SH-SY5Y cells were plated onto Hi-Q4 dishes (Ibidi
GmbH, Germany). Immediately before imaging, the cells were washed and
left in fresh medium without MG132, containing DOX and either vehicle
(0.05% DMSO), 3MA (10 mM) or bafilomycin (400 nM).
Epifluorescent and phase images (12806960 pixels) of selected cells
with aggregates were acquired twice per hour for 15 h using a BioStation
IM-Q (Nikon UK Ltd, Surrey, UK) fitted with a620/NA 0.5 Plan Fluor
objective and maintained at 37 C̊, under 5% CO2. The image sets were
analysed using ImageJ. The aggregate load was defined as the total
integrated density (area6intensity) of all aggregates in a given cell, with
aggregate boundaries determined by intensity thresholding. The
clearance time was defined as the time at which aggregates were
indistinguishable from diffuse TDP-43.
Fluorescence recovery after photobleaching
Stable SH-SY5Y EGFP–TDP-43 WT or DNLS cells were plated onto 18-
mm coverslips (1.5 thickness). To investigate protein mobility after
MG132 washout, the cells were washed and left in fresh medium
containing DOX, but without MG132, for 8–10 h before FRAP.
FRAP was performed using a Nikon A1 plus laser scanning confocal
microscope fitted with an environmental chamber maintained at 37 C̊
(Solent Scientific, Segensworth, UK). Confocal images were acquired
using a660/NA 1.4 Apo oil immersion objective, a confocal pinhole of
34.8 mm (Airy 1.2) and a 488-nm laser line. FRAP was performed using
NIS-Elements AR software (v. 4.00.04). Images of 5126512 pixels were
acquired. Five pre-bleach frames were acquired with a laser power of 1–
3%, before bleaching EGFP–TDP-43 (70 msec, 50% argon laser) using a
square region of interest (ROI) of 2 mm2. Fluorescence recovery was
followed for 1 min, with a laser power of 1–3% to minimise acquisition
bleaching.
Data analysis was performed using ImageJ with the Bio-Formats
plugin (Linkert et al., 2010). The mean intensity at each timepoint was
measured for the bleached ROI as well as for ROIs in the background and
in a neighbouring unbleached cell to correct for acquisition bleaching.
FRAP recovery curves for the bleached ROI were calculated by first
subtracting the background at each timepoint and correcting for






where It is the fluorescence intensity of the ROI at a given time, I0 is the
fluorescence intensity of the ROI immediately after bleaching and Ii is
the average fluorescence intensity of the ROI before bleaching. The data
were fitted to a one-phase exponential decay and plotted using GraphPad
Prism 6.02.
Statistical analysis
Data handling and graphical representations were performed using
Microsoft Excel unless otherwise stated. Statistical analyses as described
in the figure legends were performed using GraphPad Prism 6.02. One-
way ANOVA was performed after Bartlett’s testing for equal variance.
For both one- and two-way ANOVA, Bonferroni post-tests were used to
compare the selected data sets. Two-tailed Student’s t-tests were
performed after F-testing for equal variance and Welch’s correction
was applied where stated. The Pearson correlation test was performed
after D’Agostino and Pearson normality testing. Statistical significance
was set at P#0.05 (*P#0.05; **P#0.01; ***P#0.001). All figures were
prepared using Adobe Photoshop CS3.
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Movie S1. TDP-43 macroaggregate clearance. Live cell imaging of stable SH-SY5Y lines induced to form EGFP-TDP-43 ΔNLS 
aggregates by 48-h induction with DOX plus MG132 then washed out and followed for a further 15 in the presence of vehicle. 
Large aggregates fragmented and were cleared. Each frame of the video represents 1 h of imaging, total 15 h.
Movie S2. TDP-43 macroaggregate clearance requires autophagy. Live cell imaging of stable SH-SY5Y lines induced to form 
EGFP-TDP-43 ΔNLS aggregates by 48 h induction with DOX plus MG132 then washed out and followed for a further 15 in the 
presence of bafilomycin. Large aggregates fragmented but fragments persisted under autophagy inhibition. Each frame of the video 
represents 1 h of imaging, total 15 h.
